908 Devices Inc. (NASDAQ: MASS) reported fourth‑quarter and full‑year 2025 results that marked a historic turnaround. Revenue rose 18% YoY to $56.2 million, driven by a 21% increase in FTIR product sales and a jump in OEM and funded partnership revenue to $1.0 million from $0.7 million. The company posted its first adjusted EBITDA profit of $0.7 million in Q4, a reversal from a $4.0 million loss in the same period a year earlier, and a full‑year adjusted EBITDA loss of $9.6 million versus $15.6 million in 2024. EPS came in at $‑0.05, beating the consensus estimate of $‑0.07 by $0.02.
The quarter’s gross profit reached $9.2 million, giving a GAAP gross margin of 53%—up from 47% in Q4 2024—and an adjusted gross margin of 57%, up from 52% in the prior year. Operating expenses fell to $6.1 million, a $17.3 million reduction from $23.4 million in Q4 2024, largely due to a $10.1 million goodwill impairment charge and a reduction in the fair value of contingent consideration. Recurring revenue accounted for 35% of total sales, and the company’s cash position stood at $113 million with no debt, providing a multi‑year runway as it moves toward profitability in 2026.
Management highlighted the significance of the results. “2025 was a defining year for 908 Devices as we strengthened our operating model, expanded margins, and achieved Adjusted EBITDA positivity in the fourth quarter. Our disciplined execution led to strong growth as we achieved revenue of $56.2 million in 2025, an 18% increase year over year,” said CEO Kevin J. Knopp. CFO Joseph Griffith added, “The achievement of positive adjusted EBITDA is a critical milestone, reflecting our ongoing commitment to operational efficiency.”
Investors responded positively, citing the first adjusted EBITDA profit, the revenue beat, margin expansion, and the company’s strong balance sheet. The guidance for 2026 projects revenue of $64.5 million to $67.5 million, representing 15% to 20% growth, and reflects management’s confidence in continued demand across the vital health, safety, and defense‑tech markets.
Strategically, 908 Devices has completed a transformation focused on handheld chemical analysis tools, divesting its bioprocessing desktop assets in March 2025. Installed base growth accelerated 24% YoY to 3,736 devices, and the company projects its total addressable market to expand from $1.5 billion at IPO to $2.5 billion by 2027. These moves position 908 Devices to capture growing demand for rapid, field‑ready chemical detection amid heightened security and regulatory scrutiny.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.